Therapy Areas: Inflammatory Diseases
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
10 June 2026 - US healthcare company Organon (NYSE:OGN) on Wednesday announced US Food and Drug Administration (FDA) approval of a supplemental Biologics License Application for TOFIDENCE (tocilizumab...
Sanofi halts phase 3 MOBILIZE study of riliprubart in CIDP
10 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that it will stop the phase 3 MOBILIZE study evaluating riliprubart in patients with chron...
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
10 June 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, announced on Tuesday that its partner, Formation Bio, ...
FDA grants rare paediatric disease designation to RedHill's opaganib
...
Antengene presents first ATG-207 preclinical data at EULAR 2026
8 June 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996) announced on Sunday that it has presented the first preclinical data on ATG-207, alpha masked and TGF beta RIII...
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
5 June 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq: GILD) and biotechnology company Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT), formerly known as Galapagos, confirmed ...